XenoPort, Inc. is a biopharmaceutical company established in 1999 with a focus on developing and commercializing a range of internally discovered product candidates aimed at treating neurological disorders. The company's flagship product, Horizant® (gabapentin enacarbil) Extended-Release Tablets, has already received approval and is being marketed in the United States, while Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and marketed in Japan through a partnership with Astellas Pharma Inc. XenoPort also holds global rights to gabapentin enacarbil. Their pipeline includes potential treatments for Parkinson's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company secured a $20.00M Post-IPO Equity investment on 21 November 2012.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $20.00M | - | 21 Nov 2012 | |
| Series D | $25.00M | 1 | Notable Capital | 30 Dec 2004 |
| Series C | $37.00M | 2 |
|
14 Jan 2004 |
| Series B | $43.90M | 2 |
|
01 Jun 2002 |
| Grant | $2.00M | - | 15 Oct 2001 |
No recent news or press coverage available for XenoPort, Inc..
We care about your data, and we'd love to use cookies make your experience better.
